Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy that responds to various immunosuppressive treatments. Oral daily prednisone therapy is effective and inexpensive, but the long-term treatment that is usually necessary leads to serious adverse effects. Consequently, intravenous immunoglobulin and plasma exchange have been widely used to treat CIDP, making treatment expensive and inconvenient. A steroid regimen that reduces adverse effects but preserves efficacy would simplify treatment. Pulsed steroids have nongenomic actions not seen with low-dose steroids, including rapid inhibition of arachidonic acid release and of calcium and sodium cycling across plasma membranes of immune cells.

Objective: To study the efficacy, safety, and tolerability of pulsed oral methylprednisolone therapy in patients with CIDP.

Design: Open-label prospective study.

Setting: University of Minnesota Neuropathy Center, Minneapolis.

Patients: Ten patients (3 women and 7 men) with CIDP followed up for at least 22 months.

Main Outcome Measures: Neuromuscular score and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score were used as outcome measures for efficacy; weight, blood pressure, changes in bone density, and steroid-related adverse effect questionnaire were used as outcome measures for safety.

Results: This steroid regimen leads to significant improvement in weakness and disability in all patients treated and to off-treatment remission in 60% of patients. Treatment was fairly well tolerated, and only 1 patient discontinued treatment because of adverse effects. Steroid-induced osteoporosis remained a problem, especially in older patients.

Conclusions: Pulsed oral methylprednisolone may be efficacious in the long-term treatment of CIDP and is relatively well tolerated. Remission can be induced in most patients, especially those with a shorter duration of disease.

Arch Neurol. 2008;65(11):1460-1464
The median DS improved from a baseline of 5 (range, 1 to 7) to 1 at 1 year (P = .01) and 0 at 2 years (P = .01). One patient with a history of heartburn developed gastritis and duodenal ulceration after administration of the first dose of pulsed oral methylprednisolone, and treatment was stopped. The remaining 9 patients were treated for at least 2 years or until remission was achieved (range, 14-34 months). The mean (SD) dose at 1 year was 316 (141) mg/wk (range, 100-500 mg/wk) and at 2 years was 175 (153) mg/wk (range, 0-500 mg/wk). Only dosage of patients receiving medication was included in the calculation. None of the 9 patients discontinued treatment because of a perception of inefficacy or adverse effects.

Six of 9 patients treated with pulsed oral methylprednisolone went into remission after a mean (SD) of 27 (7.04) months of treatment (range, 14-34 months), and remission was sustained for a mean (SD) of 29 (9) months (17, 18, 31, 31, 37, and 39 months). The mean (SD) duration of disease in patients who went into remission was 4.5 (3.72) months (2, 3, 3, 3, 4, and 12 months) and in whom remission could not be induced was 68.5 (45) months (10, 72, 72, and 120 months). One patient who went into remission had relapsed at the time of this publication. One patient who went into remission had relapsed at the time of this publication.

The median NMS at baseline was 105.25 (range, 93-120). Of the 8 patients with weakness, the NMS increased in 7 at 3 months and in 1 at 6 months. At 1 year, the NMS increased in all of the patients to a median of 120 (range, 113.5-120) (P = .01). At 2 years, the median NMS was 120, and it was either stable or improved to 120 in 5 of 9 patients; it declined by a median of 2 points (range, 1-4.5 points) in 4 of 9 patients.

The median DS improved from a baseline of 5 (range, 1-7) to 1 at 1 year (P = .01) and 0 at 3 years.
Table 3. Safety of Pulsed Oral Methylprednisolone Therapy in 10 Patients With CIDP at 1 and 2 Years

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline (Median, Range)</th>
<th>1 y (Median, Range)</th>
<th>2 y (Median, Range)</th>
<th>Baseline vs 1 y</th>
<th>1 y vs 2 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight, lb</td>
<td>190 (153-264)</td>
<td>215 (158-300)</td>
<td>219 (148-243)</td>
<td>.01</td>
<td>NS</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>130 (101-142)</td>
<td>132 (123-146)</td>
<td>129 (101-142)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic</td>
<td>77 (67-94)</td>
<td>80 (72-86)</td>
<td>75.5 (62-85)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Glycated hemoglobin level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Baseline 1 y 2 y Baseline vs 1 y 1 y vs 2 y

Table 4. Adverse Effects of Pulsed Oral Methylprednisolone Therapy in 10 Patients With CIDP

<table>
<thead>
<tr>
<th>Adverse Effect</th>
<th>Patients, No.</th>
<th>Duration, d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insomnia</td>
<td>9</td>
<td>1-2</td>
</tr>
<tr>
<td>Unpleasant taste</td>
<td>9</td>
<td>1-2</td>
</tr>
<tr>
<td>Mood changes</td>
<td>6</td>
<td>1-2</td>
</tr>
<tr>
<td>Fatigue</td>
<td>5</td>
<td>1-2</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>3</td>
<td>1-3</td>
</tr>
<tr>
<td>Skin thinning</td>
<td>3</td>
<td>Long-term</td>
</tr>
<tr>
<td>Mild edema</td>
<td>3</td>
<td>Intermittent</td>
</tr>
<tr>
<td>Dyspopsia</td>
<td>3</td>
<td>1-2</td>
</tr>
<tr>
<td>Heart burn</td>
<td>2</td>
<td>1-2, with first few doses</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2</td>
<td>1-2</td>
</tr>
<tr>
<td>Moon facies</td>
<td>1</td>
<td>Long-term</td>
</tr>
<tr>
<td>Rash</td>
<td>1</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

Abbreviation: CIDP, chronic inflammatory demyelinating polyneuropathy. 
*a One patient had worsening of preexisting depression.

The results of this study suggest that pulsed oral methylprednisolone is efficacious in the long-term treatment of CIDP. Compared with daily steroid treatment, the adverse effects seem to be more acceptable to the patients. Steroid-related osteoporosis remains a problem, especially in older patients, but it may be prevented using various strategies.
mediated through a membrane receptor.\textsuperscript{11} We, therefore, sought to investigate the long-term efficacy, tolerability, and safety of pulsed oral methylprednisolone treatment in patients with CIDP.

Our data suggest that pulsed oral methylprednisolone may be an effective long-term treatment for CIDP. Of the 10 patients who participated in this study, 1 dropped out because of adverse effects, but the NMS and the DS improved in all of the other patients at 1 year. In general, onset of improvement was at least as early as 3 months in most patients and by 6 months in all patients treated.

The median NMS increased by 14\% and DS by 80\% at 1 year. In the trial comparing intravenous immunoglobulin with PLEX,\textsuperscript{12} Neurological Disability Score-Weakness (NDS-W) increased by almost 50\%. Other studies\textsuperscript{9,10} have reported a 52\% and a 32\% improvement with PLEX and intravenous immunoglobulin, respectively. The smaller improvement in the present study could be related to a lower mean NMS at baseline (NMS=106) compared with an NDS-W of 63 and 73.3 in the other studies.\textsuperscript{9,10} Another possibility is that we used a wider weakness rating scale (0-5 Medical Research Council scale), with 0.5-point increments/decrements as against the 1-, 2-, 3-, 4-point scale in NDS.

Remission was induced in 6 patients, 2 continued receiving low-dose pulsed oral methylprednisolone, 1 dropped out of the study because of adverse effects, and 1 died of unrelated causes. Duration of disease was shorter in patients in whom remission was induced, suggesting that early treatment may be important. Improvement in the 6 patients in remission was striking, without residual weakness or disability. Moreover, remission was sustained for 17 to 39 months, and at the time of this study none of the patients had relapsed. We did not find a relationship between the occurrence of remission and the age of the patient, absence of axon loss, or median nerve conduction velocity. One of 2 patients with significant axon loss and 4 of 5 patients with severe median motor conduction slowing went into remission.

Remission rates reported in the literature range from 4\% to 73\%,\textsuperscript{13-16} but they are difficult to compare with the present data because we excluded patients in partial or on-treatment remission. In this study, none of the patients in remission had weakness or disability, and they were not undergoing any immunosuppressive treatment. Also, we did not introduce other immunosuppressive treatments during pulsed oral methylprednisolone treatment, whereas patients described in the literature were treated with multiple immunosuppressive agents. Given the restrictive criteria, it is likely that the remission rates are higher, related to long-term steroid treatment allowed by the relatively improved tolerability of the regimen or to the nongenomic actions of the pulsed regimen. Patients in whom intravenous immunoglobulin had failed also responded to pulsed oral methylprednisolone therapy, and 2 of 3 patients went into remission, suggesting that pulsed oral methylprednisolone may be efficacious even in intravenous immunoglobulin failures.

Unlike with daily steroids, the treatment regimen was fairly well tolerated, with adverse effects for 2 days after treatment but none during the remainder of the week. The most common adverse effect was a syndrome of insomnia, unpleasant taste, and mood change that improved over time. Although 1 patient dropped out of the study, none of the others stopped treatment because of adverse effects. In general, although the treatment regimen was not entirely free of adverse effects, given their absence during most of the week, patients were accepting of them.

There was no significant change in blood pressure, but weight was increased at 1 year and stabilized thereafter. Patients in remission returned to their baseline weight after treatment was stopped. One patient developed diabetes mellitus after 9 months of treatment, but no significant change in glycated hemoglobin levels was seen in any of the other patients in whom data were available.

Osteoporosis occurred in 5 of 9 patients despite prophylactic treatment with calcium and cholecalciferol. Patients who developed osteoporosis were older and were undergoing pulsed oral methylprednisolone treatment for longer compared with those who did not develop osteoporosis. At 1 year, only 1 patient developed osteoporosis, and by 3 years an additional 4 patients had developed the disease. Prophylactic bisphosphonates that have been shown to prevent steroid-induced osteoporosis\textsuperscript{17} may minimize the risk of osteoporosis in these patients. Also, there is a suggestion that a lower dose of pulsed oral methylprednisolone may be sufficient because there is a ceiling effect on the nongenomic actions at the 250-mg dose.\textsuperscript{11} Use of a smaller dose and adjusting the dose more often than every 3 months may also reduce adverse effects.

In summary, pulsed oral methylprednisolone may be efficacious in the treatment of CIDP, and it induces remission in the majority of patients and significant improvement in disability in all patients treated. It is suggested that the treatment is better tolerated than daily steroids, with adverse effects that are relatively short-lived. Osteoporosis remains a problem, but various prophylactic strategies could be explored. In conclusion, given the suggestion of efficacy, a study that compares the efficacy, safety, and cost-effectiveness of pulsed oral methylprednisolone treatment with that of intravenous immunoglobulin treatment needs to be planned.

Accepted for Publication: June 20, 2008.
Correspondence: Suraj Ashok Muley, MD, Department of Neurology, University of Minnesota, MMC 295, 420 Delaware St SE, Minneapolis, MN 55455 (muley001@umn.edu).

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Muley, Kelkar, and Parry. Acquisition of data: Muley and Parry. Analysis and interpretation of data: Muley. Drafting of the manuscript: Muley. Critical revision of the manuscript for important intellectual content: Muley, Kelkar, and Parry. Statistical analysis: Muley. Administrative, technical, and material support: Muley. Study supervision: Kelkar and Parry.

Financial Disclosure: None reported.

REFERENCES

2. Dyck PJ, O'Brein PC, Oviatt KF, et al. Prednisone improves chronic inflamma-

©2008 American Medical Association. All rights reserved.

Downloaded From: http://archneur.jamanetwork.com/pdfaccess.ashx?url=/data/journals/neur/22587/ on 06/25/2017


---

**Announcement**

**Trial Registration Required.** In concert with the International Committee of Medical Journal Editors (ICMJE), *Archives of Neurology* will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as [http://ClinicalTrials.gov](http://ClinicalTrials.gov)). Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005. For trials that began enrollment before this date, registration will be required by September 13, 2005, before considering the trial for publication. The trial registration number should be supplied at the time of submission.

For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorial by DeAngelis et al in the January issue of *Archives of Dermatology* (2005;141:76-77). Also see the Instructions to Authors on our Web site: [www.archneurol.com](http://www.archneurol.com).